Basilea Announces Major Sales Achievement for Cresemba®
Basilea Pharmaceutica Ltd, a key player in the biopharmaceutical arena, recently made headlines with a significant announcement regarding its antifungal medication Cresemba® (isavuconazole). The company reported outstanding sales performance driven by its license partner, Pfizer Inc., across Europe, which has led to the triggering of a milestone payment amounting to USD 30 million. This achievement underscores both the efficacy of Cresemba in treating severe fungal infections and the demand within the healthcare market.
Key Highlights of Cresemba® Sales Performance
According to the latest market data, total global in-market sales of Cresemba reached a remarkable USD 652 million over a 12-month period. This translates to an impressive 27 percent growth year-on-year, showcasing Cresemba's increasing acceptance and utilization in clinical settings.
David Veitch, Basilea’s Chief Executive Officer, expressed his optimism about the sales trajectory, stating, “This milestone payment reflects the significant medical need and growth momentum of Cresemba in the region. We are pleased to see that our efforts are making a difference for patients facing life-threatening invasive mold infections.”
A Closer Look at Cresemba® (isavuconazole)
Cresemba (isavuconazole) is a versatile antifungal approved for both intravenous and oral administration. It stands out for its dual capability of treating invasive aspergillosis and mucormycosis, particularly in patients for whom traditional treatments, such as amphotericin B, may not be suitable. Its approval across over 70 countries, including key markets in Europe and North America, positions it as an integral component in the treatment regimens for serious fungal infections.
Basilea has established numerous licensing and distribution agreements for isavuconazole that cover approximately 115 countries, enhancing its global footprint and allowing for broader patient access to this essential medication.
About Basilea Pharmaceutica
Founded in the year 2000, Basilea Pharmaceutica is dedicated to developing innovative therapies for patients with severe infections. With a commitment to excellence, the company has successfully introduced two notable hospital medications: Cresemba for invasive fungal infections and Zevtera for bacterial infections. Furthermore, Basilea continues to expand its portfolio with both preclinical and clinical anti-infective assets, ensuring its relevance in the evolving pharmaceutical landscape.
Basilea is traded on the SIX Swiss Exchange (SIX: BSLN) and is renowned for its innovative approach to treating complex infections. The company operates with a clear mission to address unmet medical needs and improve patient outcomes.
Future Prospects for Cresemba®
The continuous growth in Cresemba's sales presents a bright outlook not only for Basilea but also for the healthcare community addressing fungal infections. With ongoing clinical studies and market expansions, Cresemba is poised to reinforce its position as a leader in the antifungal market. The commitment of Basilea and Pfizer Inc. to rigorous research ensures that patients will have access to the best treatment options available.
Frequently Asked Questions
What is Cresemba® used for?
Cresemba® (isavuconazole) is used for treating invasive aspergillosis and mucormycosis in patients who cannot undergo traditional treatment.
Who manufactures Cresemba®?
Cresemba is developed by Basilea Pharmaceutica, with licensing and distribution managed in partnership with Pfizer Inc.
What recent milestone did Basilea achieve?
Basilea achieved a USD 30 million milestone payment due to strong sales performance of Cresemba® in Europe.
How many countries is Cresemba® approved in?
Cresemba is approved and available in more than 70 countries worldwide.
How can patients access Cresemba®?
Patients can access Cresemba through healthcare providers, as it is available in hospitals and specialized clinics across regions where it is approved.
